Repository logo
 
Publication

HER2 Status in RAS and BRAF Wild-Type Metastatic Colorectal Cancer: A Portuguese Study

2023-07Journal article Open access
Simple item page
dc.contributor.authorFraga, Teresa
dc.contributor.authorSousa, Maria João
dc.contributor.authorMagalhães, Joana
dc.contributor.authorBasto, Raquel
dc.contributor.authorPaulo, Judy
dc.contributor.authorBonito, Nuno
dc.contributor.authorMagalhães, José Paulo
dc.contributor.authorFigueiredo, Paulo
dc.contributor.authorSousa, Gabriela M
dc.date.accessioned2024-06-18T09:47:02Z
dc.date.available2024-06-18T09:47:02Z
dc.date.issued2023-07
dc.description.abstractIntroduction: Colorectal cancer (CRC) is the second-most deadly cancer worldwide. However, there remains a scarcity of precision treatments available for this type of cancer. Amplification or overexpression of human epidermal growth factor receptor 2 (HER2+) is a well-established therapeutic target in gastric and breast cancer. HER2 is positive in approximately 5% of CRC cases and has been implicated in resistance to therapy with anti-epidermal growth factor receptor antibodies. The aim of this study was to evaluate HER2 status in RAS and BRAF wild-type metastatic CRC (mCRC) and its correlation with survival outcomes. Materials and methods: A single-center retrospective analysis of RAS and BRAF wild-type mCRC patients undergoing systemic treatment was conducted from July 2014 to September 2020. Tissue HER2 status was determined by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH) and/or chromogenic in situ hybridization (CISH). HER2+ was defined as IHC3 (+) or IHC2 (+) through FISH or CISH (+). Results: Fifty-nine patients were included. The median age of all the included patients was 64 years (33-82). Four patients had HER2+ tumors (7%). Four patients had HER2+ tumors (7%). The majority of HER2+ mCRC cases were males (n=3) and left-sided CRC (n=3). All patients received FOLFIRI plus cetuximab as first-line treatment. At the median follow-up of 24.0 months, patients with HER2-negative mCRC presented with a median overall survival (mOS) of 39.4 months (95% confidence interval (CI) 32.7-46.0) and the four patients with HER2+ mCRC had a mOS of 20.4 months (95% CI; 9.5-31.3; p=0.07). In HER2-negative patients, the median PFS (mPFS) was 11.3 months (95% CI; 9.2-13.4) vsHER2-positive patients with a mPFS of 10.9 months (95% CI; 1.3-20.4; p=0.47). Conclusions: To our knowledge, this is the first study reporting HER2+ in mCRC patients in a Portuguese population and the HER2+ rate was consistent with previous studies. Our study suggests that HER2+ may potentially be a marker that is able to predict poor prognosis in RAS and BRAF wild-type mCRC.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationFraga T, de Sousa MJ, Magalhães J, et al. HER2 Status in RAS and BRAF Wild-Type Metastatic Colorectal Cancer: A Portuguese Study. Cureus. 2023;15(7):e42536. doi:10.7759/cureus.42536pt_PT
dc.identifier.doi10.7759/cureus.42536pt_PT
dc.identifier.issn2168-8184
dc.identifier.urihttp://hdl.handle.net/10400.16/2951
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherCureus, Inc.pt_PT
dc.relation.publisherversionhttps://www.cureus.com/articles/163143-her2-status-in-ras-and-braf-wild-type-metastatic-colorectal-cancer-a-portuguese-study#!/pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectbraf mutationpt_PT
dc.subjectcolorectal cancerpt_PT
dc.subjecther2pt_PT
dc.subjectmetastaticpt_PT
dc.subjectPortugalpt_PT
dc.subjectraspt_PT
dc.titleHER2 Status in RAS and BRAF Wild-Type Metastatic Colorectal Cancer: A Portuguese Studypt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceUnited States of Americapt_PT
oaire.citation.issue7pt_PT
oaire.citation.startPagee42536pt_PT
oaire.citation.titleCureuspt_PT
oaire.citation.volume15pt_PT
person.familyNameSousa
person.givenNameMaria João
person.identifier.orcid0000-0003-1125-2871
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication8f36b51c-7ffc-4a9d-aa12-d9a7ecced3ca
relation.isAuthorOfPublication.latestForDiscovery8f36b51c-7ffc-4a9d-aa12-d9a7ecced3ca

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Fraga-2023-Her-status-in-ras-and-braf-wild-typ.pdf
Size:
251.88 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.44 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

SOnc - Artigos publicados em revistas indexadas na Pubmed/Medline